Citadel Advisors
FBRX icon

Citadel Advisors’s Forte Biosciences FBRX Stock Holding History

Citadel Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-124
Closed -$1.67K – 14497
2024
Q2 		$1.67K Buy
124
+84
+210% +$1.36K ﹤0.01% 13791
2024
Q1 		$701 Sell
40
-428
-91% -$7.47K ﹤0.01% 14267
2023
Q4 		$9.61K Sell
468
-720
-61% -$10.1K ﹤0.01% 13143
2023
Q3 		$19.7K Buy
1,188
+488
+70% +$10.8K ﹤0.01% 12641
2023
Q2 		$18.2K Sell
700
-56
-7% -$1.46K ﹤0.01% 12814
2023
Q1 		$19.1K Sell
756
-1,792
-70% -$45.1K ﹤0.01% 13100
2022
Q4 		$63.7K Buy
2,548
+720
+39% +$18.5K ﹤0.01% 11836
2022
Q3 		$49K Sell
1,828
-332
-15% -$10.5K ﹤0.01% 11645
2022
Q2 		$70K Buy
2,160
+1,236
+134% +$39.3K ﹤0.01% 11706
2022
Q1 		$34K Sell
924
-2,384
-72% -$90.2K ﹤0.01% 13034
2021
Q4 		$177K Sell
3,308
-4,692
-59% -$316K ﹤0.01% 12035
2021
Q3 		$592K Buy
+8,000
New +$4.43M ﹤0.01% 9453
2020
Q2 		– Sell
-32
Closed -$15K – 9982
2020
Q1 		$15K Buy
+32
New +$12.5K ﹤0.01% 9358
2019
Q4 		– Sell
-677
Closed -$168K – 9290
2019
Q3 		$168K Buy
677
+614
+975% +$932K ﹤0.01% 8243
2019
Q2 		$158K Sell
63
-83
-57% -$246K ﹤0.01% 8329
2019
Q1 		$597K Buy
+146
New +$564K ﹤0.01% 6490

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Citadel Advisors's FBRX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Forte Biosciences (FBRX) in Q1 2026: 233,369 shares worth $6.04M. The stake represents ﹤0.01% of the portfolio and ranks #4031 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in FBRX as recently as Q3 2025.

Citadel Advisors first reported a position in FBRX in Q3 2018 and has held it in 21 quarters since. The position peaked at $16.5M in Q3 2020. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Citadel Advisors held 233,369 shares of Forte Biosciences worth $6.04M as of Q1 2026.
  • Forte Biosciences was a new Citadel Advisors position in Q1 2026.
  • Forte Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4031 holding.
  • Citadel Advisors first reported a position in Forte Biosciences in Q3 2018 and has held it in 21 quarters since.
  • Citadel Advisors's Forte Biosciences position peaked at $16.5M in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.